Biotechnology company Wilk was awarded patent approval for Methods and Systems for in-Vitro Milk Production from the U.S. Patent and Trademark Office. 

Wilk (formerly known as Biomilk) is developing industrial processes for producing both human and animal milk from milk-producing mammary cells. 

Its technology enables the production of real milk with all its components and ingredients, while reducing greenhouse emissions, preserving natural resources, and improving the overall quality of animal life. The exclusive patent covers the research methods and technologies for cultured milk and breastmilk production.

"The patent approval represents the culmination of years of intensive investment in research and development,” said Tomer Aizen, CEO of Wilk.  “It’s also a sign of the confidence in Wilk's production processes. This will strengthen our reputation as a leader in the field of cell-based milk production, and bringing us one step closer to the ultimate goal of revolutionizing the dairy industry."

The patent provides the required long-term protection and reinforcement of Wilk's intellectual property and IP protection systems. The company is submitting additional applications for patent approvals, including one for Methods for Increasing the Production of Milk in a Cultured System, with the goal of increasing production of essential milk components.

Wilk is planning for production of both regular cultured milk and specially cultured human breastmilk with the key components that nurture infant health and development. The company launched operations in 2020 and is publicly traded on the Tel Aviv Stock Exchange under the ticker symbol "WILK."

For more information: wilkismilk.com